32 results on '"Bartelheim K"'
Search Results
2. Intraoperative Immuntherapie mit dem trifunktionalen Antikörper Catumaxomab bei Patienten mit fortgeschrittenem Magen-, Colon- und Pankreaskarzinom: Ergebnisse einer Phase I Pilotstudie
3. Rhabdoid 2007 and EU-RHAB - results of two European registries with consensus treatment recommendations for 139 children with rhabdoid tumors
4. Genetic alterations of SMARCA4 in atypical teratoid/rhabdoid tumours (AT/RT) are associated with higher frequency of germ line alterations and shorter survival as compared to SMARCB1 deficient AT/RT
5. Longterm remission of high risk AT/RT despite inoperability and widespread metastasis - the EU-RHAB strategy
6. Hippo signaling is essential for the phenotype associated with SNR1 loss in drosophila melanogaster and involved in the biology of SMARCB1-deficient atypical teratoid/rhabdoid tumors
7. Favorable outcome of patients affected by rhabdoid tumors due to rhabdoid tumor predisposition syndrome (RTPS)
8. Treatment options and clinical outcome in infants with AT/RT
9. Detection of SMARCB1 loss in ascites cells in the diagnosis of an abdominal rhabdoid tumor
10. Intraoperative Immuntherapie mit dem trifunktionalen Antikörper Catumaxomab bei Patienten mit fortgeschrittenem Magen-, Colon- und Pankreaskarzinom: Ergebnisse einer Phase I Pilotstudie
11. High-Dose Chemotherapy (HDCT) with autologous peripheral Blood Stem Cell Transplantation (APBSCT) in Children weith Atypical Teratoid/Rhabdoid Tumors (AT/RT) : A report from the European Rhabdoid registry (EU-RHAB)
12. EU-RHAB: Ergebnisse des europäischen Verbundprojektes zur Erfassung und Behandlung von Kindern mit Rhabdoiden Tumoren
13. Clinical Characteristics and Outcome of Children with Extracranial, Extrarenal Rhabdoid Tumors Registered to the European Rhabdoid Registry 2007–2013
14. ATYPICAL TERATOID RHABDOID TUMOUR
15. Feasibility of Intensive Multimodal Therapy in Infants Affected by Rhabdoid Tumors – Experience of the EU-RHAB registry
16. Intraoperative Immuntherapie mit dem trifunktionalen Antikörper Catumaxomab bei Patienten mit fortgeschrittenem Magen-, Colon- und Pankreaskarzinom: Ergebnisse einer Phase I Pilotstudie
17. ATYPICAL TERATOID RHABDOID TUMOR (ATRT)
18. Intraoperative, adjuvant treatment of gastric cancer with the trifunctional antibody catumaxomab compared to surgery alone: A phase II study
19. Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GI-tract cancer and peritoneal carcinomatosis: A matched-pair analysis
20. Treatment of peritoneal carcinomatosis due to GI-tract cancer by intraperitoneal application of the trifunctional antibody catumaxomab (anti-EpcAM x anti-CD3): Results of a phase I/II trial
21. Phase Ib study of the anti-neovascular agent MBT-0206 to evaluate safety and efficacy in patients with metastatic breast cancer
22. Phase I study of the anti-neovascular agent MBT-0206 to evaluate safety and efficacy in patients with metastatic or advanced unresectable gastrointestinal cancer (GI cancer)
23. Improved 6-year overall survival in AT/RT - results of the registry study Rhabdoid 2007.
24. Detection of SMARCB1 loss in ascites cells in the diagnosis of an abdominal rhabdoid tumor.
25. Synchronous congenital malignant rhabdoid tumor of the orbit and atypical teratoid/rhabdoid tumor--feasibility and efficacy of multimodal therapy in a long-term survivor.
26. Clinical and genetic features of rhabdoid tumors of the heart registered with the European Rhabdoid Registry (EU-RHAB).
27. SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis.
28. Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1.
29. Identification of genes involved in the biology of atypical teratoid/rhabdoid tumours using Drosophila melanogaster.
30. Favorable outcome of patients affected by rhabdoid tumors due to rhabdoid tumor predisposition syndrome (RTPS).
31. High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors.
32. Nine months to progression using fourth-line liposomally encapsulated paclitaxel against hepatocellular carcinoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.